Delivering Anti-Infectives

to Patients in Need​

AiCuris is an international clinical-stage biopharmaceutical company, dedicated to the development of novel, therapeutic candidates for the prevention and treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients.
The Company is focused on advancing its highly differentiated product portfolio, leveraging its research and clinical development expertise to bring game-changing, high growth potential product candidates to the market and thereby to vulnerable patients with a high need for anti-infectives treatment options.

  • Demonstrated ability in delivering novel treatment options:
    PREVYMIS® (letermovir), the Company’s first-in-class antiviral agent for prophylactic use in allogeneic hematopoietic stem cell (HSC) and kidney transplant patients, prevents life-threatening cytomegalovirus (CMV) reactivation, is marketed by MSD (tradename of Merck & Co., Inc.) and generates increasing revenues.
  • Candidate with fast track to market:
    Pritelivir, a proprietary product candidate for the treatment of acyclovir resistant herpes simplex virus (HSV) infections in immunocompromised patients is currently in phase 3 development and obtained FDA breakthrough designation. Launch preparations have been initiated at AiCuris.
  • Innovative pipeline of anti-infectives:
    The anti-sense oligonucleotide (ASO) AIC468 aims to prevent active infection of BK virus (BKV) in kidney transplanted patients and is expected to enter clinical testing early next year. Preclinical programs targeting Adenovirus infections are positioned to aim to treat transplant patients, as well as ocular infections in the general population.

With a solid financial position and highly experienced management team, AiCuris is on its way to becoming a fully integrated biopharmaceutical company covering the entire value chain from research through clinical development to commercialization.

Latest News


„AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement“

The cooperation provides us with the opportunity to combine exceptional German antiviral research with our development capabilities and clinical expertise to develop novel therapies for immunocompromised patients.

Read more


AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS®

PREVYMIS® received european approval for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk.

Read more


AiCuris Senior Management heading to San Francisco for the J.P. Morgan Annual Healthcare Conference from January 8th–11th

Meet with our CEO Larry Edwards and CFO Sabrina Kuttruff-Coqui at the J.P. Morgan Annual Healthcare Conference.

Read more


AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients

Young start-ups and academic teams can apply to the AiCubator program starting from October 1st to December 31st, 2023.

Read more


AiCuris Received €30 Million Milestone Payment from Partner MSD Following U.S. FDA Approval of PREVYMIS® in Second Indication

PREVYMIS® now approved for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk

Read more


AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives Treatments for Immunocompromised Patients

Company will advance its highly differentiated product portfolio, including a proprietary phase 3 candidate with fast track to market.

Read more


STI & HIV 2023 World Congress 2023, 24-27 July in Chicago, USA

Meet our Head of Research, Alexander Birkmann, at his talk about Pritelivir for the treatment of resistant HSV infections in immunocompromised patients.

Read more